NCT05976568View on ClinicalTrials.gov

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

668

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2027

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

QL1706

7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Bevacizumab

15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Oxaliplatin injection

85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle

DRUG

Capecitabine

1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle

DRUG

Sintilimab

200 mg administered as IV infusion on Day 1 of each 21-day cycle

Trial Locations (2)

200032

Zhongshan Hospital, Fudan University, Shanghai

211199

Nanjing Tianyinshan Hospital, Nanjing

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT05976568 - A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter